Profile
| Metric | Value |
|---|---|
| Full Name | AbCellera Biologics Inc. |
| Ticker | NASDAQ: ABCL |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Canada |
| IPO | |
| Indexes | Not included |
| Website | abcellera.com |
| Employees | 596 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $4.20 | |
| Price, 1D Change | -7.08% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.50 | |
| Revenue | $29M | |
| Revenue, 1Y Change | -24.17% | |
| EPS | -$0.55 | |
| EPS, 1Y Change | -9.28% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.55 | |
| EPS Estimate | -$0.65 | |
| EPS Est. Change | -17.93% | |
| Revenue | $28.83M | |
| Revenue Estimate | $36.06M | |
| Revenue Est. Change | +25.07% | |
| Current Price | $4.20 | |
| Price Target | - | $9.50 |
| Price Tgt. Change | - | +126.19% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.47 | -$0.51 | -7.72% | |
| -$0.59 | -$0.55 | +6.68% | |
| -$0.65 | N/A | -17.93% | |
| -$0.69 | N/A | -24.71% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $38.13M | $38.03M | -0.28% | |
| $31.58M | $28.83M | -8.70% | |
| $36.06M | N/A | +25.07% | |
| $56.31M | N/A | +95.31% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +40.00% | |
| Price, 3Y | -59.54% | |
| Market Cap, 1Y | +41.69% | |
| Market Cap, 3Y | -57.78% | |
| Revenue, 1Y | -24.17% | |
| Revenue, 3Y | -92.32% | |
| EPS, 1Y | -9.28% | |
| EPS, 3Y | -214.77% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $4.20 | |
| SMA 200 | $3.78 | |
| SMA 200 vs Price | -9.90% | |
| SMA 50 | $3.85 | |
| SMA 50 vs Price | -8.40% | |
| Beta | 1.50 | |
| ATR | $0.24 | |
| 14-Day RSI | 71.60 | |
| 10-Day Volatility | 79.53% | |
| 1-Year Volatility | 78.04% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $28.83M | |
| EPS | -$0.55 | |
| Gross Profit | $28.83M | |
| Gross Margin | -236.42% | |
| Operating Profit | -$301.15M | |
| Operating Margin | -1,044.45% | |
| Net Income | -$162.86M | |
| Net Margin | -564.83% | |
| EBITDA | -$204.15M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 9.81 | |
| Quick Ratio | 9.81 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 4.89 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 35.59 | |
| PB Ratio | 1.30 | |
| EV/EBITDA | -3.88 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.06B | |
| Cash & Equivalents | $156.33M | |
| Total Assets | $1.36B | |
| Current Assets | $751.37M | |
| Total Liabilities | $154.58M | |
| Current Liabilities | $76.61M | |
| Total Debt | $65.36M | |
| Short Term Debt | $4.62M | |
| Accounts Payable | $34.35M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $329.98M | |
| Operating Expenses | $329.98M | |
| Cost Of Goods Sold | $97.00M | |
| SG&A | $85.49M | |
| D&A | $97.00M | |
| Interest Expense | $0.00 | |
| Income Tax | -$37.54M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$108.56M | |
| CFI | $121.41M | |
| CFF | $12.77M | |
| Capex | $78.40M | |
| Free Cash Flow | -$186.95M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Leerink Partners | → | |
| Stifel | → | |
| Keybanc | → | |
| Truist Securities | → | |
| Stifel | → | |
| Keybanc | → | |
| Benchmark | → | |
| Stifel | → | |
| Keybanc | → | |
| Stifel | → |
Analyst sentiment
Institutional ownership
Screeners with ABCL
Data Sources & References
- ABCL Official Website www.abcellera.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1703057/000170305725000025/0001703057-25-000025-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1703057/000162828025008689/0001628280-25-008689-index.htm
- ABCL Profile on Yahoo Finance finance.yahoo.com/quote/ABCL
- ABCL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/abcl
FAQ
What is the ticker symbol for AbCellera Biologics Inc.?
The ticker symbol for AbCellera Biologics Inc. is NASDAQ:ABCL
Does AbCellera Biologics Inc. pay dividends?
No, AbCellera Biologics Inc. does not pay dividends
What sector is AbCellera Biologics Inc. in?
AbCellera Biologics Inc. is in the Healthcare sector
What industry is AbCellera Biologics Inc. in?
AbCellera Biologics Inc. is in the Biotechnology industry
What country is AbCellera Biologics Inc. based in?
AbCellera Biologics Inc. is headquartered in Canada
When did AbCellera Biologics Inc. go public?
AbCellera Biologics Inc. initial public offering (IPO) was on December 11, 2020
Is AbCellera Biologics Inc. in the S&P 500?
No, AbCellera Biologics Inc. is not included in the S&P 500 index
Is AbCellera Biologics Inc. in the NASDAQ 100?
No, AbCellera Biologics Inc. is not included in the NASDAQ 100 index
Is AbCellera Biologics Inc. in the Dow Jones?
No, AbCellera Biologics Inc. is not included in the Dow Jones index
When was AbCellera Biologics Inc. last earnings report?
AbCellera Biologics Inc.'s most recent earnings report was on November 6, 2025
When does AbCellera Biologics Inc. report earnings?
The next expected earnings date for AbCellera Biologics Inc. is February 26, 2026